



FDA
AUTHORIZED

For adjunctive use in adults age 22+ on ADT¹

Tap into the brain's power to take on MDD symptoms¹

Rejoyn may strengthen
connections in the brain by
harnessing neuroplasticity.¹⁻³

Rejoyn is an app that uses
brain-training exercises
to help enhance cognitive
control of emotion.¹



Not a real patient.

ADT=antidepressant therapy; MDD=major depressive disorder.

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

See the [Clinician Brief Summary](#).

 Rx ONLY

Meet Rejoyn™

When used alongside ADT, Rejoyn can help patients treat their MDD symptoms differently.¹



Taps into neuroplastic potential¹

The cognitive-emotional training (CET) exercises in Rejoyn are designed to **target dysregulated neural networks** in the brain.



6-week treatment¹

Rejoyn is a **6-week adjunctive treatment authorized by the FDA** that patients complete on their smartphone.



Reduced MDD symptoms¹

In a clinical trial, adding Rejoyn to ADT **reduced MDD symptoms** with **zero adverse events** related to Rejoyn.




Learn more about the trial results [here](#).

ADT=antidepressant therapy;
MDD=major depressive disorder.



Patients can download the Rejoyn app on the **App Store** or **Google Play**.




Designed to target dysregulated neural networks in the brain¹

Dysregulation has been associated with MDD.¹

Imaging of patients with MDD has shown¹:

Hypoactivity in cognitive areas, like the prefrontal cortex.

Hyperactivity in emotion centers, like the amygdala.



Dysregulated connectivity between the amygdala and the prefrontal cortex can cause **impaired cognitive control of emotion**.¹

Tapping into neuroplastic potential may reduce MDD symptoms¹

The cognitive-emotional training (CET) exercises in Rejoyn™ are designed to simultaneously activate the amygdala and the prefrontal cortex.¹



Brain Exercise

⌚ ~20-30 min



Repeated **coordination of both regions** over 6 weeks may **strengthen their connection**.¹




This is thought to help **enhance cognitive control of emotion**, which may help **reduce MDD symptoms**.¹

MDD=major depressive disorder.

Cognitive-emotional training (CET) exercises

Over the course of 6 weeks, Rejoyn™ helps treat MDD symptoms with CET exercises and cognitive behavioral therapy (CBT)-based video lessons.¹

The CET exercises are a working memory task with human facial expressions as stimuli and recall of the emotion displayed as the response.¹



What patients can expect from the CET exercises¹:

- 3× PER WEEK
- ~20-30 MINUTES EACH
- Patients are prompted to identify and recall a sequence of faces portraying certain emotions¹
- Rejoyn will adjust its difficulty based on patient performance to ensure that the exercises remain challenging but doable¹




Want to see inside Rejoyn?

Watch [this video](#) to see how the app works.



MDD=major depressive disorder.



Cognitive behavioral therapy (CBT)-based video lessons

The CBT-based video lessons teach principles that are designed to be internalized and applied.¹



What patients can expect from the CBT-based video lessons¹:

-  3 × PER WEEK
-  ~5 MINUTES EACH

-  Each video lesson is followed by a prompt that encourages an out-of-app task or guides the user through an audio psychotherapy activity¹
-  After the 6-week treatment period ends, patients can return to the CBT-based video lessons for an additional 4 weeks¹

CBT-based video lessons

The lessons in Rejoyn™ are designed to help patients learn and apply therapeutic skills. Topics include^{1,4}:

- Emotion regulation
- Behavioral activation
- Cognitive restructuring

Treatment schedule

Rejoyn™ is 6 weeks of treatment, but how your patient sets up those 6 weeks is up to them.¹

Recommended

Your patients can choose to do 1 task per day, which will switch between cognitive emotional training (CET) exercises and cognitive behavioral therapy (CBT)-based video lessons.¹



Alternate

Patients also have the option of completing 1 lesson and 1 exercise per day if they want to get ahead or catch up.^{1*}



¹*Patients cannot do more than 1 lesson and 1 exercise on a given day.



End-to-end nurse support

In the app, patients can sign up to receive support calls from a nurse. These calls may include a **welcome call, help with onboarding, and regular check-ins** as patients progress through the 6-week treatment.

Patients can call the nurse support line at **1-833-Y-REJOYN (1-833-973-5696)**. Available Monday through Friday, 8 AM to 8 PM ET, excluding holidays.

Prescribing Rejoyn™

Prescriptions must be sent directly to **CaryRx pharmacy**, the online pharmacy that dispenses access codes for Rejoyn.

Step 1

Find CaryRx pharmacy in the electronic medical record (EMR) system

- Confirm CaryRx pharmacy details
 - Name: **CaryRx**
 - Address: **1300 7th St NW, Suite 200, Washington, DC 20001**
 - Phone: **1-202-930-4242**
 - NCPDP number: **0905250**

Step 2

Fill out a prescription

COMPLETED REJOYN PRESCRIPTION EXAMPLE	
Product name: Rejoyn	Quantity: 1
NDC or catalog number: 57335000512	Refills: 0
Dosage: 70 days	Sig: Use as directed.
Be sure your patient's mobile number is populated in the EMR system. It will be used by CaryRx pharmacy to contact the patient and provide them with an access code.	




You may call in or fax the prescription directly to CaryRx pharmacy.
Phone: 1-202-930-4242 | Fax: 1-202-930-4243



Behavioral health clinicians can recommend Rejoyn to their patients and direct them to the Rejoyn patient website. There they can follow a link to schedule a virtual consult from Wheel, a telehealth provider, for a \$29 fee.

What happens next

Once a prescription has been sent to CaryRx pharmacy, the pharmacy will begin the process of providing Rejoyn™ to your patient.



Rejoyn is \$200 for the full 6 weeks

If your patient's insurance doesn't cover Rejoyn, they can use REJOYN75 at the pharmacy check out to get Rejoyn for \$50.*

*The limited time offer is available until June 30, 2025, to those who do not pay for Rejoyn through insurance. Your patients may pay less if their insurance covers Rejoyn. The pharmacy will automatically check their coverage when processing the prescription.

FSA=flexible spending account; HSA=health savings account.

Not a real patient.





If you or your patients have questions or need help, support is available.

Please call **1-833-Y-REJOYN**
(1-833-973-5696) Monday through Friday,
8 AM to 8 PM ET, excluding holidays.

Learn more at
RejoynHCP.com

INDICATION: Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.

SAFETY INFORMATION: Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

See the [Clinician Brief Summary](#).

References: 1. Rejoyn. Clinician brief summary. Otsuka Precision Health, Inc; 2024. 2. Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging neuroplasticity to enhance adaptive learning: the potential for synergistic somatic-behavioral treatment combinations to improve clinical outcomes in depression. *Biol Psychiatry*. 2019;85(6):454-465. doi:10.1016/j.biopsych.2018.09.004 3. Hoch MM, Doucet GE, Moser DA, et al. Initial evidence for brain plasticity following a digital therapeutic intervention for depression. *Chronic Stress (Thousand Oaks)*. 2019;3:2470547019877880. doi:10.1177/2470547019877880 4. Forbes A, Docherty J, Iacoviello B, Carpenter DC, Ward MJ, inventors; Otsuka America, Inc., Click Therapeutics, Inc., assignees. Systems and methods for treating depression using a digital therapeutic. US patent application 20240047041A1. February 8, 2024.



The Apple logo is a trademark of Apple Inc., registered in the United States and other countries. App Store is a service mark of Apple Inc., registered in the United States and other countries. Google Play and the Google Play logo are trademarks of Google LLC.



Otsuka Precision Health, Inc.

© 2025 Otsuka Precision Health, Inc. All rights reserved.

December 2024

20US24EBP0152